稳定性冠心病血运重建:PCI与CABG的机制差异与预后影响
本文综述对比PCI与CABG在稳定性冠心病中的机制差异,指出仅CABG能延长生存,其机制可能并非通过改善缺血或存活心肌,而是通过预防心肌梗死;多数心梗源于非限流性狭窄,PCI仅处理限流病变故难以显著减少新发心梗,而CABG可提供“外科侧支化”来预防心梗并延长生命。
要点
- 仅CABG被证实可延长稳定性冠心病患者生存,PCI不能。
- 多数心梗由非限流性狭窄引起,PCI仅针对限流病变难以预防新发心梗。
- CABG可能通过提供“外科侧支化”预防心梗,从而延长生存。
核心结论
- CABG可能通过提供“外科侧支化”预防心肌梗死,从而延长稳定性冠心病患者生命,而PCI不能。
研究设计与样本
- 本文为JACC综述,汇总比较CABG与PCI或药物治疗的研究证据。
主要发现
- 存活心肌和/或缺血检测未能准确预测CABG或PCI的治疗效果,对血运重建改善生存的机制提出疑问。
- 多数心肌梗死由非限流性狭窄引起,而PCI仅专注于治疗限流性病变。
- 所有显示CABG有生存获益的CABG对比PCI或药物治疗的研究,同时也显示心梗减少。
临床怎么用
- 在稳定性冠心病血运重建决策中,应认识到PCI与CABG机制可能不同,CABG可能通过预防心梗延长生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are considered revascularization procedures, but only CABG can prolong life in stable coronary artery disease. Thus, PCI and CABG mechanisms may differ. Viability and/or ischemia detection to guide revascularization have been unable to accurately predict treatment effects of CABG or PCI, questioning a revascularization mechanism for improving survival. By contrast, preventing myocardial infarction may save lives. However, the majority of infarcts are generated by non-flow-limiting stenoses, but PCI is solely focused on treating flow-limiting lesions. Thus, PCI cannot be expected to significantly limit new infarcts, but CABG may do so through providing flow distal to vessel occlusions. All comparisons of CABG to PCI or medical therapy that demonstrate survival effects with CABG also demonstrate infarct reduction. Thus, CABG may differ from PCI by providing "surgical collateralization," prolonging life by preventing myocardial infarctions. The evidence is reviewed here.
引用
- Doenst T, Haverich A, Serruys P, et al. PCI and CABG for Treating Stable Coronary Artery Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2019. PMID: 30819365. doi:10.1016/j.jacc.2018.11.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。